Results 41 to 50 of about 26,603 (276)

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis [PDF]

, 2013
AIMS/HYPOTHESIS: Sulfonylureas are widely prescribed glucose-lowering medications for diabetes, but the extent to which they improve glycaemia is poorly documented.
R. J. Stevens, Farmer, AJ, Stevens, Richard, Hirst, JA, Hirst, Jennifer, Dyar, A, A. J. Farmer, Lung, TWC, A. Dyar, Stevens, RJ, J. A. Hirst, Farmer, Andrew, T. W. C. Lung, Lung, TW   +13 more
core   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

Revealing the role of increased SK3 expression in sulfonylurea resistance triggered by prolonged exposure

Nutrition & Diabetes
Background Sulfonylureas have long been utilized in the management of type-2 diabetes mellitus (T2DM) due to their insulin-secretagogue properties. However, their clinical efficacy is hindered by the risk of severe hypoglycemia and secondary sulfonylurea
Jung Gyu Park, Minseok Kim, Sungje Yoo, Sun Wook Hwang, Jongsoo Mok, Joonghoon Park, Keon Wook Kang   +6 more
doaj   +1 more source

Potencial de uso dos herbicidas chlorimuron-ethyl, imazethapyr e cloransulam-methyl na cultura do feijão Potential use of chlorimuron-ethyl, imazethapyr and cloransulam-methyl in common bean crop

Planta Daninha, 2009
O objetivo deste trabalho foi avaliar a seletividade dos herbicidas chlorimuron-ethyl, imazethapyr e cloransulam-methyl, aplicados em associação com o herbicida fomesafen, a dez cultivares de feijão.
S.O. Procopio, A.J.B.P. Braz, A.L.L. Barroso, A. Cargnelutti Filho, K.L. Cruvinel, M. Betta, G.B.P. Braz, J.J.S. Fraga Filho, L.D. Cunha Júnior   +8 more
doaj   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

In Vitro Evaluation of Drug–Drug Interaction Between Gliclazide and Antacids at the Absorption Level

Pharmaceuticals
Background: The antidiabetic drug gliclazide is often taken with antacids due to its gastrointestinal side effects. However, patients rarely report antacid use, making drug–drug interactions a potential cause of therapy failure.
Slavica Lazarević, Srđan Kosijer, Maja Đanić, Dragana Zaklan, Bojan Stanimirov, Momir Mikov, Nebojša Pavlović   +6 more
doaj   +1 more source

Reasoned Opinion on the review of the existing maximum residue levels (MRLs) for amidosulfuron according to Article 12 of Regulation (EC) No 396/2005 [PDF]

EFSA Journal, 2014
According to Article 12 of Regulation (EC) No 396/2005, the European Food Safety Authority (EFSA) has reviewed the Maximum Residue Levels (MRLs) currently established at European level for the pesticide active substance amidosulfuron.
European Food Safety Authority
doaj   +1 more source

Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics

, 2016
Drug-drug interactions causing severe hypoglycemia due to antidiabetic drugs is a major clinical and public health problem. We assessed whether sulfonylurea use with a statin or fibrate was associated with severe hypoglycemia. We conducted cohort studies
S Cardillo, Brensinger, Colleen M., Bilker, Warren B., S Hennessy, Gagne, Joshua J., Cardillo, Serena, X Han, Leonard, Charles E., CE Leonard, Han, Xu, JH Flory, JJ Gagne, DA Flockhart, Flockhart, David A., WB Bilker, Hennessy, Sean, CM Brensinger, Flory, James H.   +17 more
core   +1 more source

Mechanism of KATP hyperactivity and sulfonylurea tolerance due to a diabetogenic mutation in L0 helix of sulfonylurea receptor 1 (ABCC8) [PDF]

, 2011
Activating mutations in different domains of the ABCC8 gene-coded sulfonylurea receptor 1 (SUR1) cause neonatal diabetes. Here we show that a diabetogenic mutation in an unexplored helix preceding the ABC core of SUR1 dramatically increases open ...
Vaxillaire, Martine, Martine Vaxillaire, Babenko, Andrey P., Andrey P. Babenko   +3 more
core   +1 more source